Clicky

Pyxis Oncology, Inc.(PYXS)

Description: Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunology Solid Tumors Immunotherapy Cancer Treatment Monoclonal Antibody Non Small Cell Lung Cancer Immunotherapies Acute Myeloid Leukemia Antineoplastic Drugs Small Cell Lung Cancer Treatment Of Non Small Cell Lung Cancer Antibody Drug Conjugate Treatment Of Acute Myeloid Leukemia Soft Tissue Sarcoma Blood Cancers Preclinical Stage Biotechnology

Home Page: www.pyxisoncology.com

PYXS Technical Analysis

35 Cambridgepark Drive
Cambridge, MA 02140
United States
Phone: 617 221 9059


Officers

Name Title
Mr. John L. Flavin M.B.A., MBA, Ph.D. Co-Founder & Independent Chairman
Dr. Lara S. Sullivan M.D., MBA CEO, Pres & Director
Ms. Pamela Yanchik Connealy M.B.A. Chief Financial Officer
Dr. Jay M. Feingold M.D., Ph.D. Chief Medical Officer
Mr. Jitendra Wadhane Chief Accounting Officer, Sr. VP of Fin. & Corp. Controller
Dr. Balu N. Balasubramanian Ph.D. Interim Chief Technology Officer
Dr. Jan Pinkas Ph.D. Chief Scientific Officer
Ms. Martina Molsbergen B.S. Interim Chief Bus. Officer
Dr. Charles T. Gombar Ph.D. Sr. VP of Portfolio & Program Management

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.2176
Price-to-Sales TTM: 0
IPO Date: 2021-10-08
Fiscal Year End: December
Full Time Employees: 73
Back to stocks